Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

85.5K
Overview
85.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.1K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.

Science translational medicine·2023
Same author

Characterizing piggyBat-a transposase for genetic modification of T cells.

Molecular therapy. Methods & clinical development·2022
Same author

Donor T cells for CAR T cell therapy.

Biomarker research·2022
Same author

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy.

ImmunoTargets and therapy·2021
Same author

Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2020

Related Experiment Video

Updated: Mar 9, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K

Increasing Stem Cell Dose Promotes Posttransplant Immune Reconstitution.

Ning Xu1, Sylvie Shen1,2, Alla Dolnikov1,2,3

  • 11 Sydney Cord & Marrow Transplant Facility, Centre for Children's Cancer & Blood Disorders, Sydney Children's Hospital , Randwick, Australia .

Stem Cells and Development
|December 22, 2016
PubMed
Summary

Increasing umbilical cord blood stem cell numbers enhances hematopoietic and immune recovery after transplantation. Higher doses promote better T cell development and maintain naive T cells, crucial for robust immune responses.

Keywords:
cord bloodhematopoietic stem cellimmune reconstitution

More Related Videos

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

1.0K
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
22:06

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells

Published on: February 25, 2007

14.1K

Related Experiment Videos

Last Updated: Mar 9, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

1.0K
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
22:06

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells

Published on: February 25, 2007

14.1K

Area of Science:

  • Hematology
  • Immunology
  • Stem Cell Transplantation

Background:

  • Umbilical cord blood (UCB) is a vital source of hematopoietic stem cells (HSCs) for patients lacking related donors.
  • UCB transplantation is limited by low HSC numbers, impacting engraftment and immune reconstitution, especially in adults.
  • The precise effect of HSC dose on immune recovery post-UCB transplant remains incompletely understood.

Purpose of the Study:

  • To investigate the impact of hematopoietic stem cell (HSC) numbers in umbilical cord blood (UCB) transplants on hematopoietic and immune reconstitution.
  • To determine how varying HSC doses influence immune cell differentiation and T cell pool maintenance.

Main Methods:

  • Utilized immunocompromised mice transplanted with purified UCB CD34+ stem cells.
  • Administered varying doses of CD34+ stem cells to assess dose-dependent effects.
  • Analyzed hematopoietic and immune reconstitution, including immune cell populations and T cell subsets.

Main Results:

  • Increased CD34+ cell numbers in UCB transplants significantly promoted hematopoietic and immune reconstitution.
  • Higher stem cell doses favored B cell generation early post-transplant, while lower doses yielded more myeloid and T cells.
  • Enhanced CD8+ T cell development and preservation of naive T cells were observed with higher stem cell doses.
  • Ex vivo expanded CD34+ cells delayed immune reconstitution, suggesting loss of critical lymphoid precursors.

Conclusions:

  • The number of HSCs in a UCB transplant graft is a critical factor modulating stem cell differentiation and immune reconstitution.
  • Optimizing HSC dose is essential for improving hematopoietic recovery, immune reconstitution, and maintaining a functional naive T cell pool.
  • Ex vivo expansion strategies need refinement to preserve primitive lymphoid precursors for effective immune reconstitution.